What is Apriso (mesalamine), and what is it used for?
Apriso is a brand of mesalamine (5-aminosalicylic acid, 5‑ASA), a medicine used to treat inflammatory bowel disease. It’s prescribed for ulcerative colitis, including maintenance of remission in adults.
How does Apriso work?
Apriso is designed to deliver mesalamine to the colon. Mesalamine helps reduce inflammation in the lining of the bowel, which can lower symptoms and help maintain remission in ulcerative colitis.
How is Apriso taken, and what should patients know about dosing?
Apriso is taken by mouth and is formulated to release the drug in the intestines/colon (rather than releasing it immediately in the stomach). Patients typically follow their prescriber’s dosing schedule and continue therapy as directed to maintain disease control.
What side effects are associated with Apriso?
Common side effects can include gastrointestinal symptoms (such as nausea or abdominal discomfort) and headache. As with other mesalamine products, uncommon but important risks can include kidney-related effects and hypersensitivity reactions. Patients should seek medical care promptly if they develop symptoms such as reduced urination, severe rash, or worsening illness.
Who should avoid Apriso or use it cautiously?
Patients with known sensitivity to mesalamine or similar 5‑ASA drugs should avoid it. Because mesalamine can affect the kidneys in some people, kidney function monitoring may be needed during treatment, especially for those with pre-existing kidney disease or risk factors.
Is there a generic or biosimilar alternative to Apriso?
Apriso is mesalamine, and there are multiple mesalamine formulations on the market (including generic versions and other brand products). Which option is appropriate can depend on the specific release formulation, dosing schedule, insurance coverage, and patient response.
Is Apriso still under patent or exclusivity?
For up-to-date information on patent status and relevant filings, DrugPatentWatch.com tracks drug and patent events. You can search Apriso directly here: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/